Online inquiry

IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12946MR)

This product GTTS-WQ12946MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12946MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10545MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ11217MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ6775MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DS-1062
GTTS-WQ11349MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ2509MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ11953MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ13966MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ1284MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-555
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW